By Stephen Nakrosis

Shares of Acceleron Pharma Inc. (XLRN) are moving higher in Friday's market, following the U.S. Food and Drug Administration's announcement it had approved Reblozyl for the treatment of anemia patients with beta thalassemia who require regular red blood cell transfusions.

Celgene Corp. (CELG) and Acceleron are jointly developing Reblozyl, the companies said.

At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade at $43.05.

Celgene shares were up 0.35%, to $109.38, following the news.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 08, 2019 13:15 ET (18:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.